The Company has received in-principle approval from BSE Limited for issue of equity shares to promoters and non-promoters on preferential basis.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.6 pts more than Nifty Microcap 250 and 6.2 pts more than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Genesis IBRC India Limited has received in-principle approval from BSE Limited to issue 4,02,50,000 equity shares on a preferential basis. These shares will be allotted to both promoters and non-promoters, meaning existing shareholders will see their holdings diluted. The approval was granted on March 12, 2026, and the company informed the exchange on March 13, 2026, under Regulation 30 of SEBI LODR. The issue is being carried out under Regulation 28 of SEBI LODR. The actual issue price, use of funds, and identities of the allottees are not disclosed in this particular filing.
This is a capital-raising move that will dilute existing shareholders' stakes, with the stock price reaction depending on the eventual issue price and the purpose for which the raised funds will be used. Investors should track the next filings for allotment details and pricing.